Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
High-dose interleukin-2 can be effective in selected metastatic renal cell cancer patients pre-treated with VEGF-targeted agents, reveals research presented today at the ESMO Symposium on Immuno-Oncology in Geneva, Switzerland.
New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland
The possibilities for personalised vaccines in all types of cancer are revealed today in a lecture from Dr Harpreet Singh at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland
Immunotherapy is set to revolutionise the treatment of cancer, according to ESMO President Professor Rolf A. Stahel. His comments come as the ESMO Symposium on Immuno-Oncology 2014 is about to open in Geneva, Switzerland tomorrow.
ESMO announced today that it will be organising an annual Congress in Europe starting in 2016
A record number of 19,859 attendees at the ESMO 2014 Congress discussed changes to oncology that will soon have a positive impact on the care of patients around the world.
Corrigendum: Please note the updated data for the response rate is 52% instead of 43%
Patients with HER2 positive breast cancer derive less benefit from anti-HER2 drugs when they have PIK3CA mutations
Important new data from two trials evaluating different treatment approaches in metastatic colorectal cancer provide reassurance for clinicians that current treatment choices are valid, and confirm that molecular characterisation of such tumours is vital
Dabrafenib anti-tumour activity in BRAF V600E mutation-positive non-small cell lung cancer; HER2 inhibition shows promise in HER2-positive non-small cell lung cancer
Preliminary data from a phase III trial suggest drug is well tolerated and leads to a sustained response in patients who have progressed after ipilimumab therapy
High-dose radiotherapy adds no survival benefit after chemotherapy and radical surgery; PD-L1 protein a possible immunotherapy target
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
